Jun Ma is an Academician of the Chinese Academy of Sciences (Division of Life Science and Medicine), Professor of Radiation Oncology and deputy president of Sun Yat-sen University Cancer Center, Director of the Key Laboratory of Multidisciplinary Diagnosis and Treatment of Nasopharyngeal Carcinoma, Member of the ASCO Asia Pacific Regional Council and the ASCO Plenary Series Scientific Review Committee, President-designate of NPC Gordan Research Conference, Executive Director of the ninth Council of the Chinese Anti-Cancer Association (CACA), Member of the Fourth Council of the Chinese Society of Clinical Oncology (CSCO), Convener of the 8th Discipline Evaluation Group (Special Medicine Group) of the Academic Degrees Committee of the State Council, Member of the Department of Life Medicine of the 8th Science and Technology Committee of the Ministry of Education, chairman of the First Committee of the Nasopharyngeal Carcinoma of the Chinese Society of Clinical Oncology (CSCO), chairman of the Fifth Committee of the Nasopharyngeal Carcinoma of the Chinese Anti-Cancer Association (CACA), and co-chairman of the Chinese Society of Clinical Oncology and American Society of Clinical Oncology (CSCO-ASCO) Nasopharyngeal Cancer Clinical Diagnosis and Treatment Guidelines Committee.

Precise diagnosis, radiotherapy, immunotherapy, and individualized management combining multiple treatment modalities of nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in NPC. Preclinical basic research focusing on biomarkers, prognostic molecules, and signal pathways related to NPC development.

06/2000-06/2002 Postdoctoral fellow in Radiation Oncology, Anderson Cancer Center, Houston, TX (Mentor: Dr. Nicholas H. A. Terry)

07/1987-09/1990 Master Degree of Oncology, Sun Yat-sen University of Medical Sciences, Guangzhou, China (Mentor: Dr. Huaqin Ming)

07/1980-09/1985 Bachelor of Medicine, Hu Nan Medical University, Changsha, China

1. Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Z, Li JB, Liu N, Xie FY, Guo R, Sun Y, Ma J (Corresponding author). Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025;1–13. (IF 503.1) 

2. Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J (Corresponding author). Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet, 2024, 403(10445): 2720-2731. (IF 98.4)

3. Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J (Corresponding author). Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303-313. (IF 98.4)

4. Chen YP, Chan AT, Le QT, Blanchard P, Sun Y, Ma J (Corresponding author). Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80. (IF 98.4)

5. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J (Corresponding author). Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Eng J Med. 2019;381(12):1124-1135. (IF 96.2)

6. Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J (Corresponding author). Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023;380:e072133. (IF 93.6)

7. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J (Corresponding author). Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. BMJ. 2018;363:k4226. (IF 93.6)

8. Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J (Corresponding author). Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328(8):728-736. (IF 63.1)

9. Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, Liang XY, Zhang Y, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N, Li GB, Kuang DM, Sun Y, Ma J (Corresponding author). The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29(6):1424-1436. (IF 58.7)

10. Chen YP, Wang YQ, Lv JW, Li YQ, Chua M, Le QT, Lee N, Colevas AD, Seiwert T, Hayes D, Riaz N, Vermorken J, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N, Ma J (Corresponding author). Identification and Validation of Novel Microenvironment-based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy. Ann Oncol. 2019;30:68-75. (IF 56.7)

11. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J (Corresponding author). A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26(1):205-11. (IF 56.7)

12. Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, Zhen ZC, Li WF, Tang LL, Mao YP, Chen L, Guo R, Zhang LL, Ai XL, Wu SY, Hao MY, Wei DH, Li JB, Chen YP, Zhou GQ, Sun Y, Ma J (Corresponding author). Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024; 2024;42(8):1401-1414.e4. (IF 48.8)

13. Du XJ, Wang GY, Zhu XD, Han YQ, Lei F, Shen LF, Yang KY, Chen L, Mao YP, Tang LL, Li L, Wu Z, Xu GQ, Zhou Q, Huang J, Guo R, Zhang Y, Liu X, Zhou GQ, Li WF, Xu C, Lin L, Chen YP, Chen FP, Liang XY, Chen SY, Li SQ, Cui CY, Li JB, Ren J, Chen MY, Liu LZ, Sun Y, Ma J (Corresponding author). Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma. Cancer Cell. 2024 11;42(3):464-473. (IF 48.8)

14. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J (Corresponding author). Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39(7):840-859. (IF 42.1)

15. Ma J (First & corresponding author), Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY, Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma, J Clin Oncol. 2001; 19(5): 1350-1357. (IF 42.1)

16. Tang LL, Huang CL, Zhang N, Jiang W, Wu YS, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L, Zhou GQ, Ma J (Corresponding author). Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479-490. (IF 41.6)

17. Tang XR, Li YQ, Liang SB, Jiang W, Liu F, Ge WX, Tang LL, Mao YP, He QM, Yang XJ, Zhang Y, Wen X, Zhang J, Wang YQ, Zhang PP, Sun Y, Yun JP, Zeng J, Li L, Liu LZ, Liu N, Ma J (Corresponding author). Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382-393. (IF 41.6)

18. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J (Corresponding author). Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11):1509-1520. (IF 41.6)

19. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J (Corresponding author). Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. (IF 41.6)

20. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J (Corresponding author). Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13(2):163-71. (IF 41.6)

21. Huang SW, Jiang W, Xu S, Zhang Y, Du J, Wang YQ, Yang KY, Zhang N, Liu F, Zou GR, Jin F, Wu HJ, Zhou YY, Zhu XD, Chen NY, Xu C, Qiao H, Liu N, Sun Y, Ma J (Corresponding author), Liang YL, Liu X. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. Signal Transduct Target Ther. 2024 Oct 23;9(1):285. (IF 40.8)

22. Zhang P, He Q, Wang Y, Zhou G, Chen Y, Tang L, Zhang Y, Hong X, Mao Y, He Q, Yang X, Liu N, Ma J (Corresponding author). Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduct Target Ther. 2022;7(1):46. (IF 40.8)

23. Tang LL, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J (Corresponding author). Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MR imaging. Radiology. 2010; 257(1):151-7. (IF 29.1)

24. Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K, Kuang DM, Li GB, Liu N, Ma J (Corresponding author). Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020 Nov;30(11):1024-1042. (IF 28.1) 

25. Liu N, He QM, Chen JW, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Ma J (Corresponding author). Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer. 2014; 13:111. (IF 27.7)

26. Liu N, Jiang N, Guo R, Jiang W, He QM, Xu YF, Li YQ, Tang LL, Mao YP, Sun Y, Ma J (Corresponding author). MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013; 12(1):123. (IF 27.7)

27. Chen YP, Lv JW, Mao YP, Li XM, Li JY, Wang YQ, Xu C, Li YQ, He QM, Yang XJ, Lei Y, Shen JY, Tang LL, Chen L, Zhou GQ, Li WF, Du XJ, Guo R, Liu X, Zhang Y, Zeng J, Yun JP, Sun Y, Liu N, Ma J (Corresponding author). Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021;20(1):14. (IF 27.7)

28. Liu X, Zhang Y, Tang LL, Le QT, Chua ML, Wee JT, Lee NY, O’Sullivan B, Lee AW, Sun Y, Ma J (Corresponding author). Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018; 4(8): 1073-1079. (IF 22.5)

29. Liu X, Chen YP, Li WF, Sun Y, Guo Y, Eisbruch A, Ma J (Corresponding author). Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncol. 2017; 3(3):414-416. (IF 22.5)

30. Liu X, Le QT, Ma J (Corresponding author). Focus on the Number of Radiation Oncology Trials or on Clinical Relevance-Reply. JAMA Oncol. 2018;4(12):1791-1792. (IF 22.5)

31. Chen YP, Shen JY, Deng ZJ, Sun Y, Liang XY, Lv JW, Ma J (Corresponding author). Low-dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma. Cancer Commun (Lond). 2022 Oct;42(10):909-912. (IF 20.1)

32. Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, Du XJ, Fang WF, Feng M, Gao J, Han F, He X, Hu CS, Hu DS, Hu GY, Jiang H, Jiang W, Jin F, Lang JY, Li JG, Lin SJ, Liu X, Liu QF, Ma L, Mai HQ, Qin JY, Shen LF, Sun Y, Wang PG, Wang RS, Wang RZ, Wang XS, Wang Y, Wu H, Xia YF, Xiao SW, Yang KY, Yi JL, Zhu XD, Ma J (Corresponding author). The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41(11):1195-1227. (IF 20.1)

33. Zhang Y, Sun Y, Ma J (Corresponding author). Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond). 2019;39(1):39. (IF 20.1)

Chen Q, Tang L, Liu N, Han F, Guo L, Guo S, Wang J, Liu H, Ye Y, Zhang L, Liu L, Wang P, Li Y, He Q, Yang X, Tang Q, Li Y, Liang Y, Sun X, Xie C, Mo Y, Guo Y, Sun R, Mo H, Cao K, Guo X, Zeng M, Mai H, Ma J (Corresponding author). Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study. Cancer Commun (Lond). 2018;38(1):66. (IF 20.1)

Last updated: Jan 2025 by International Office, Sun Yat-sen University Cancer Center